ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1941

Clinical Evaluation of Anti-Aminoacyl tRNA Synthetase Antibodies in Japanese Patients with Connective Tissue Diseases

Masakazu Matsushita, Toshio Kawamoto, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antibodies, autoimmune diseases and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Anti-Jo-1 antibody is an autoantibody specifically detected in sera of patients with polymyositis/dermatomyositis (PM/DM). The antigen corresponding to this autoantibody is histidyl-tRNA synthase, being an aminoacyl-tRNA synthase (ARS), which occurs in the cytoplasm of eukaryotes. Many autoantibodies directed to other ARS have been identified in recent years, and the condition of patients positive for these antibodies is currently termed anti-ARS antibody syndrome in that such condition is characterized by clinical features of pulmonary lesions and cutaneous manifestations. This study was performed to evaluate the clinical usefulness of determination of serum anti-ARS antibody levels in patients with PM/DM or other connective tissue diseases.

Methods: The study included 197 outpatients with connective tissue diseases at this hospital. Of them, 62 patients had PM/DM, 39 had systemic lupus erythematosus (SLE), 31 had rheumatoid arthritis (RA), 21 had Sjögren’s syndrome (SjS), 12 had progressive systemic sclerosis (SSc), 11 had mixed connective tissue disease (MCTD), 7 had vasculitis syndrome, 5 had Behçet’s disease, 4 had adult-onset Still’s disease, and 5 had other diseases. Determination of anti-ARS antibodies was carried out using Myositis Profile 3 Euroline Blot Test Kit commercially available from EUROIMMUN (Lubeck, Germany), in accordance with the manufacturer’s instructions. For each clinical entity concerned, anti-ARS antibody positivity rate, antinuclear antibody staining pattern, the presence/absence of concurrent interstitial pneumonia (IP), and dose levels of the corticosteroids or immunosuppressants used were assessed.

Results: Anti-ARS antibodies were detected with a significantly higher frequency among PM/DM patients with concurrent IP. Positivity for anti-ARS antibodies was observed even among RA patients with clinical signs of IP. Patients with PM/DM in whom cytoplasmic stain with antinuclear antibody was evident were frequently positive for anti-ARS antibodies other than anti-Jo-1 antibody even if they had negative results for this antibody. In patients negative for cytoplasmic staining, however, no other anti-ARS antibodies were detected. In patients with PM/DM complicated by IP positive for anti-ARS antibodies, the dosage of corticosteroids and percentage of patients receiving immunosuppressant therapy tended to be higher as compared with those negative for anti-ARS antibodies.

Conclusion: The present data suggest that the determination of serum anti-ARS antibody levels is clinically useful even in patients with IP-complicated connective tissue disease other than PM/DM. A strong association of the autoantibodies with pulmonary lesions was noted particularly in RA patients. The results also suggest that determination of serum anti-ARS antibody levels may be less necessary in myositis patients showing no positive cytoplasmic staining in the antinuclear antibody test using HEp-2.


Disclosure:

M. Matsushita,
None;

T. Kawamoto,
None;

K. Yamaji,
None;

N. Tamura,
None;

Y. Takasaki,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-evaluation-of-anti-aminoacyl-trna-synthetase-antibodies-in-japanese-patients-with-connective-tissue-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology